BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
BioVaxys Reports Positive Phase 2 Data for Maveropepimut + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
Surface Metals to Present at Fastmarkets Global Lithium, Battery & Critical Materials Conference in Las Vegas, Nevada
Nine Mile Metals Announces Completion of DDH WD-26-02,Intersecting 234.15 Meters of Visual Mineralization and Discovers a New Copper Rich VMS Horizon at the Wedge Mine
Freegold intersects 336.8 m grading 1.32 g/t Au starting from 26.5 m in Infill Drilling at Golden Summit
